Skip to main content

Enlivex Therapeutics Ltd. (ENLV)

NASDAQ: ENLV · IEX Real-Time Price · USD
6.89 -0.25 (-3.50%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap126.30M
Revenue (ttm)n/a
Net Income (ttm)-11.82M
Shares Out18.33M
EPS (ttm)-0.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,150
Open7.11
Previous Close7.14
Day's Range6.81 - 7.24
52-Week Range6.20 - 29.40
Beta0.51
AnalystsBuy
Price Target33.00 (+379.0%)
Earnings Daten/a

About ENLV

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for lif...

IndustrySoftware
IPO DateDec 12, 1995
CEODror Mevorach
Employees50
Stock ExchangeNASDAQ
Ticker SymbolENLV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ENLV stock is "Buy" and the 12-month stock price forecast is 33.00.

Price Target
$33.00
(378.96% upside)
Analyst Consensus: Buy

News

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New Engla...

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

1 month ago - GlobeNewsWire

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that compa...

2 months ago - GlobeNewsWire

Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

2 months ago - Zacks Investment Research

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critica...

Nes-Ziona, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macroph...

2 months ago - GlobeNewsWire

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macropha...

2 months ago - GlobeNewsWire

Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy

Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors?

3 months ago - Zacks Investment Research

Enlivex Therapeutics Stock Jumps On Initiation Of Another Mid-Stage COVID-19 Trial

The Israeli Ministry of Health has signed off Enlivex Therapeutics Ltd's (NASDAQ: ENLV) Phase 2b trial evaluating Allocetra in severe and critical COVID-19 patients with the acute respiratory distressed...

3 months ago - Benzinga

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomize...

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today reported that after r...

3 months ago - GlobeNewsWire

Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update

Nes Ziona, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that finan...

3 months ago - GlobeNewsWire

Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manu...

Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar Life...

4 months ago - GlobeNewsWire

Enlivex to Present at the ARDS Drug Development Summit 2021

Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Co...

4 months ago - GlobeNewsWire

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Compan...

6 months ago - GlobeNewsWire

Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Grant provides $1.1 million in non-dilutive funding for 2021

6 months ago - GlobeNewsWire

Enlivex To Study Allocetra Combined With Checkpoint Inhibitors In Solid Tumor Settings

Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. A...

8 months ago - Benzinga

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combin...

Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancers that do not respond to stand-alone checkpoint inhibitor therapies. Collaborat...

8 months ago - GlobeNewsWire

Bet on Black With These 7 Risky Stocks

These 7 risky stocks have solid fundamentals for long term growth. Use their drops now as an entry point into new highs.

Other symbols:AYXCLXKCMGNIRKTU
8 months ago - InvestorPlace

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination...

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies ...

9 months ago - GlobeNewsWire

Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's ...

Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macropha...

9 months ago - GlobeNewsWire

Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares

Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

9 months ago - GlobeNewsWire

Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares

Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

9 months ago - GlobeNewsWire

Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares

Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

9 months ago - GlobeNewsWire

Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical CO...

Phase II (16 patients treated, 9/16 (56%) with severe illness, 7/16 (44%) with critical illness, follow-up period of 28 days post-AllocetraTM treatment)

10 months ago - GlobeNewsWire

Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Compa...

10 months ago - GlobeNewsWire

Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv

– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and extre...

11 months ago - GlobeNewsWire